Aether Industries Limited has signed an exclusive manufacturing agreement with Chemoxy International Limited, a subsidiary of the SEQENS Group. According to a recent stock exchange announcement, Aether will produce a range of natural bio-based products exclusively for SEQENS under a take-or-pay contract.
The agreement, effective for an initial three-year term, will see production begin within the next 10 months, targeting an annual volume of over 100 metric tons. SEQENS, headquartered in France, is a leading global player in Health, Personal Care, and Specialty Ingredients, operating 16 production facilities and 9 R&D centers around the world.
The group reported annual revenues of €1.1 billion. The partnership leverages an innovative manufacturing process developed jointly by Aether and SEQENS over the past three years. This collaboration is a significant development for Aether’s renewables and sustainability segment, further establishing its position as a prominent Indian specialty chemical manufacturer committed to sustainable and carbon-neutral solutions.
Aether Industries Limited is a prominent Indian specialty chemicals manufacturer renowned for its focus on advanced chemical synthesis and innovative solutions. Established with a commitment to delivering high-quality, sustainable products,
Aether specializes in producing a wide range of specialty chemicals, including those used in pharmaceuticals, agrochemicals, and other industrial applications. The company is distinguished by its strong emphasis on research and development, enabling it to offer cutting-edge, tailor-made solutions to its clients.
Aether’s dedication to sustainability and environmental responsibility is reflected in its efforts to develop carbon-neutral and eco-friendly chemistry solutions, positioning it as a leader in the specialty chemicals sector in India.
